United States, September 14, 2026 /MarketersMEDIA/ -- Protheragen, a Contract Research Organization (CRO) focusing on preclinical obesity research, launched a new integrated system combining Bioanalysis of Anti-Obesity Therapeutics with a comprehensive range of obesity models. The company’s target market includes pharmaceutical and biotechnology organizations, to help them overcome the challenges of the obesity therapeutics market. More than one billion people globally are obese, and the demand for new effective and safe therapies is growing. Organizations developing obesity therapies often face clinical trial failures due to insufficient or problematic preclinical data. This system has been specifically developed to address those challenges. It provides an integrated service from biological modeling to data analysis. Protheragen’s aim is to reduce the challenges organizations encounter when generating data required for regulatory submissions.
Beginning a study with the correct models is critical. Protheragen has numerous, highly diverse, customizable obesity models that accurately reflect the pathophysiology of obesity. In vivo models are categorized by induction method (e.g., diet-induced, hypothalamic injury, or drug injection). Gene-edited models are further grouped by the genes that were targeted (e.g., single, multiple, transgenic, or chromosomal); by the inducing factors (high-fat, high-sugar, and chemical-induced); as well as by the species category of the model (mammalian and non-mammalian). There are in vitro models, which include adipocyte cell lines (e.g., 3T3-L1), hepatocytes, and pancreatic islet cells, and these can be used to study lipid metabolism, gene expression, and signaling pathways. This robust foundation of obesity models gives researchers the confidence to screen anti-obesity drugs, investigate mechanisms of action, and evaluate therapeutic efficacy with precision.
Protheragen extends its obesity models platform to offer an end-to-end service to assess the safety and efficacy of new therapies through bioanalytical services. The service supports the entire drug development process from discovery to preclinical studies. The integrated service includes PK/PD studies using advanced LC-MS/MS and HPLC techniques to characterize ADME properties and exposure-response relationships—data that directly support mechanism-of-action studies. Immunogenicity is assessed using validated ligand-binding assays, including ELISA-based anti-drug antibody (ADA) screening and confirmation, with surface plasmon resonance (SPR) employed for binding kinetics and epitope characterization. In addition, a thorough toxicity assessment is conducted from in vitro to in vivo studies. All bioanalytical assays are rigorously validated to meet regulatory requirements for precision, accuracy, and reproducibility. This ensures that the client receives quality and critical data essential to advance the timeline of drug development.
To integrate bioanalytical services for anti-obesity therapeutics and its validated obesity models, Protheragen provides clients with high-quality data and decision-making tools to optimize therapy development. The company takes great responsibility in protecting the integrity of the drug development process and is fully compliant with all quality assurance and regulatory mandates. The company emphasizes a collaborative and tailored approach, working closely with clients to understand their unique needs and providing personalized solutions from custom assay development to professional data interpretation. All services are intended for preclinical research use only and are not for diagnostic or treatment purposes.
About Protheragen
Protheragen is a specialized Contract Research Organization dedicated to advancing preclinical research in the field of obesity. Drawing on deep expertise across metabolism, inflammation, and cardiovascular biology, the company delivers high-quality data, actionable insights, and tailored solutions to support the development of obesity therapeutics. To learn more about how Protheragen's services can accelerate your drug development program, please visit https://www.obesityscientific.com/ or contact the team today to discuss your specific research needs.
Contact Info:
Name: Anna White
Email: Send Email
Organization: Protheragen
Website: https://www.obesityscientific.com/
Release ID: 89203214
In case of identifying any errors, concerns, or inconsistencies within the content shared in this press release that necessitate action or if you require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team is committed to addressing your concerns within 8 hours by taking necessary actions diligently to rectify any identified issues or supporting you with the removal process. Delivering accurate and reliable information remains our top priority.
